Alkor Bio, Ltd.

Diagnostic kit «PharmacoGENE-CYP2C9» is aimed for genetic diagnostics of individual susceptibility for indirect anticoagulants (warfarin). 

Presence of allelic polymorphisms CYP2C9*2 (+430С/Т) and CYP2C9*3 (+1075А/С) in CYP2C9 gene leads to a significant decrease of a cytochrome isoenzyme activity. It by-turn increases an expected anticoagulating effect up to seven times and can be the reason for complications development, for example extensive internal bleeding. 

Analysis of allelic polymorphisms in CYP2C9 gene is made by means of Real-Time PCR. 

It is recommended to use «PharmacoGENE-CYP2C9» diagnostic kit together with «PharmacoGENEVKORC1».

Analysis is intended for:

• Adjustment of primary indirect anticoagulants dosage for patients with high risk of thrombosis, thrombotic complications or ischemic stroke development; 

• Adjustment of drug dosage for patients diagnosed with ciliary arrhythmia, those who went through heart valve replacement surgery; 

• Adjustment of drug dosage for postexposure prophylaxis of cardiovascular episodes at patients who had acutec coronary syndrome; 

• Adjustment of drug dosage for patients with unwanted reactions for medication in family or personal anamnesis.